Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last?

Core Insights - Tarsus Pharmaceuticals, Inc. (TARS) shares experienced a significant increase of 10.9%, closing at $65.17, with trading volume surpassing the average [1] - The rise in stock price is linked to positive investor sentiment regarding the strong market performance of Tarsus' product, Xdemvy, which generated $181 million in sales in the first half of 2025, indicating a substantial year-over-year growth [2] Company Performance - Tarsus Pharmaceuticals is projected to report a quarterly loss of $0.38 per share, reflecting a year-over-year increase of 37.7%, while revenues are expected to reach $112.8 million, marking a 134.4% increase from the previous year [3] - The consensus EPS estimate for Tarsus has remained stable over the last 30 days, suggesting that stock price movements may not sustain without changes in earnings estimates [4] Industry Context - Tarsus Pharmaceuticals operates within the Zacks Medical - Biomedical and Genetics industry, where another company, Arcutis Biotherapeutics, Inc. (ARQT), saw a decline of 6.3% in its stock price, despite a 31.1% return over the past month [4] - Arcutis Biotherapeutics has an unchanged EPS estimate of -$0.09 for its upcoming report, which represents a 72.7% improvement from the previous year [5]